View Cart  

Genentech Will Pay $20 Million to Settle Rituxan Whistleblower Case

A A
Genentech has agreed to pony up $20 million to the U.S. government to settle a qui tam suit alleging kickbacks for off-label promotion of its cancer drug Rituxan.

To View This Article:

Login

Subscribe To Drug Industry Daily